胰高血糖素样肽1受体激动剂在2型糖尿病中的治疗进展被引量：6

原文传递

导出

摘要全球糖尿病和肥胖的患病率均在不断增长，根据世界卫生组织2016年最新公布的全球糖尿病报告显示，全球糖尿病患病率为8．5％，

作者李红时立新

机构地区贵州医科大学附属医院内分泌代谢病科

出处《中华糖尿病杂志》 CAS CSCD 2016年第11期658-661,共4页 CHINESE JOURNAL OF DIABETES MELLITUS

关键词 2型糖尿病胰高血糖素样肽1 受体激动剂糖尿病患病率治疗世界卫生组织

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1高妍,宁光,贾伟平,李光伟,刘志民,田浩明,刘超,马建华,郭晓蕙,郑以漫,骆天红.单用二甲双胍或二甲双胍加磺脲类药物血糖控制不佳的2型糖尿病患者加用艾塞那肽的疗效和安全性的临床研究[J].中国糖尿病杂志,2012,20(11):857-861. 被引量：12
2黄斌,孟然,冯斌,胡明月,沈山梅,毕艳,朱大龙.艾塞那肽对肥胖大鼠白色脂肪自噬及棕色化的影响[J].中华糖尿病杂志,2016,8(2):81-86. 被引量：6

二级参考文献25

1Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs, 2007, 67: 935-954.
2RA. DeFronzo, RE Ratner, J. Han, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care,2005, 28: 1092-1100.
3JB. Buse, MS. Fineman, RR. Henry, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004, 27: 2628-2635.
4DM. Kendall, MC. Riddel, J. Rosenstock, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 2005, 28: 1083-1091.
5B. Zinman, BJ. Hoogwerf, GS. Duran, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med, 2007, 146: 477-485.
6Cousin B, Cinti S, Morroni M, et al. Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization[J]. 'i Cell Sci,1992,103 (Pt 4): 931-942.
7Vosselman MJ, van Marken Lichtenbelt WD, Schrauwen P. Energy dissipation in brown adipose tissue: from mice to men [J]. Mol Cell Endocrinol,2013,379(1-2):43-50. DOI:10.1016/j. mce.2013.04.017.
8van Marken Lichtenbelt WD, Schrauwen P. Implications of nonshivering thermogenesis for energy balance regulation in humans [J]. Am J Physiol Regul Integr Comp Physiol,2011,301 (2):R285-296.
9DOh 10.1152/ajpregu.O0652.2010. Anderson ZL, Clements ,IN. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes[J]. JAAPA, 20"14,27(6):44-46. DOh10.1097/01.JAA.0000443811.42907. a5.
10Flint A, Raben A, Rehfeld ,IF, et al. The effect of glucagon- like peptide-1 on energy expenditure and substrate metabolism in humans[J]. Int J Obes Relat Metab Disord,2000, 24(3):288-298.